Mono Pharmacare Ltd
Pharmaceuticals & Biotechnology | Small Cap
Mono Pharmacare Ltd demonstrates a mixed financial performance. The company shows remarkable growth in revenue, operating profit, EPS, assets and net income. Profitability is generally strong, supported by good gross profit margins, ROCE, ROE, operating margin and net margin. The company's solvency position appears reasonable, indicating a balanced approach to debt and equity. However, liquidity is a concern, as reflected in lower cash and operating cash flow ratios. Efficiency metrics are weak, particularly in inventory and receivables management. The company's coverage ratios are also somewhat low, suggesting a limited ability to cover interest and dividend payments. Overall, Mono Pharmacare exhibits strong growth and profitability but needs to address its liquidity and efficiency challenges to ensure sustainable financial health.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio4.00
- Profitability Ratio9.60
- Efficiency Ratio3.67
- Coverage Ratio4.40
- Solvency Ratio7.90
- Liquidity Ratio4.36
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursBearish
- 4 HoursBearish
- 1 DayBearish
- 1 WeekNeutral
- 1 MonthNeutral
Mono Pharmacare Ltd demonstrates a mixed financial performance. The company shows remarkable growth in revenue, operating profit, EPS, assets and net income. Profitability is generally strong, supported by good gross profit margins, ROCE, ROE, operating margin and net margin. The company's solvency position appears reasonable, indicating a balanced approach to debt and equity. However, liquidity is a concern, as reflected in lower cash and operating cash flow ratios. Efficiency metrics are weak, particularly in inventory and receivables management. The company's coverage ratios are also somewhat low, suggesting a limited ability to cover interest and dividend payments. Overall, Mono Pharmacare exhibits strong growth and profitability but needs to address its liquidity and efficiency challenges to ensure sustainable financial health.
Overall Valuation Score
P/E RATIO (TTM)
N/A
Industry Median
28.93
Small Cap Median
26.92
P/E RATIO
6.26
P/B RATIO
0.62
Industry Median
3.18
Small Cap Median
2.63
P/S RATIO
0.12
Industry Median
3.41
Small Cap Median
2.40
Others
PEG RATIO
0.00
EV/EBITDA RATIO
5.60
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹10.95 as on Jun 18, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company exhibits strong growth across multiple dimensions. This robust growth suggests that the company is successfully expanding its market presence and capitalizing on opportunities. The company is well-positioned for continued success and value creation.
| Growth Ratios | Mar 2024 | Mar 2025 |
|---|---|---|
| Revenue Growth Rate | 351.85 | 37.7 |
| Operating Profit Growth Rate | 200 | 33.33 |
| Earnings Per Share (EPS) Growth | 142.11 | 26.81 |
| Asset Growth Rate | 28.57 | 35.8 |
| Net Income Growth Rate | 100 | 50 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial performance is characterized by modest earnings per share, limited book value per share, and a focus on capital expenditures. The company is investing heavily in its operations. This strategic focus on reinvestment could drive future growth and profitability.
| Financial Ratios | Mar 2024 | Mar 2025 |
|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 1.11 | 1.67 |
| Cash Earnings Per Share (Cash EPS) | 1.11 | 1.67 |
| Book Value Per Share | 15.56 | 17.78 |
| Dividend Per Share (DPS) | 0 | 0 |
| Capital Expenditures (CapEx) | 0.2 | 0.2 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company exhibits strong profitability. The company is capable of generating profits from its sales. Investors are more likely to be attracted to the company due to its strong financial performance.
| Profitability Ratios | Mar 2024 | Mar 2025 |
|---|---|---|
| Gross Profit Margin | 4.92 | 4.76 |
| Return on Capital Employed (ROCE) | 6.97 | 7.15 |
| Return on Equity (ROE) | 7.21 | 9.44 |
| Return on Assets (ROA) | 7.41 | 7.27 |
| Operating Margin | 4.92 | 4.76 |
| Net Margin | 1.64 | 1.79 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company demonstrates a high level of efficiency in utilizing its fixed assets to generate revenue. However, there are significant challenges in managing inventory and receivables. The company faces difficulties in efficiently converting sales into cash. These inefficiencies can tie up working capital and negatively impact profitability.
| Efficiency Ratios | Mar 2024 | Mar 2025 |
|---|---|---|
| Fixed Asset Turnover Ratio | 122 | 168 |
| Inventory Turnover Ratio | 3.09 | 3.32 |
| Receivables Turnover Ratio | 4.52 | 4.54 |
| Days Sales in Inventory Ratio | 118.12 | 109.94 |
| Receivable Days | 80.75 | 80.4 |
| Capital Turnover Ratio | 1.42 | 1.5 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's ability to meet its interest expenses is reasonable, but its dividend coverage is non-existent. It can comfortably handle its debt obligations, but it does not currently distribute dividends to shareholders. The company's financial flexibility is limited by its dividend policy.
| Coverage Ratios | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Interest Coverage Ratio | 2 | 2 | 2 |
| Equity Dividend Coverage Ratio | N/A | N/A | N/A |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency position demonstrates a balanced approach to financial leverage. It indicates a healthy mix of debt and equity financing. The company's ability to meet its long-term obligations. The business has a solid foundation with low debt compared to its assets.
| Solvency Ratios | Mar 2024 | Mar 2025 |
|---|---|---|
| Debt Ratio | 0.38 | 0.45 |
| Debt to Equity Ratio | 0.61 | 0.82 |
| Equity Ratio | 0.62 | 0.55 |
| Debt To Asset Ratio | 0.21 | 0.24 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position reveals a mixed picture. While they can cover their short term liabilities with their short term assets, its ability to quickly convert assets into cash is somewhat limited. The company struggles to generate positive operating cash flow, posing challenges for day-to-day operations. The absence of cash reserves further constrains its financial flexibility.
| Liquidity Ratios | Mar 2024 | Mar 2025 |
|---|---|---|
| Current Ratio | 2.2 | 2.07 |
| Quick Ratio | 1.05 | 1.03 |
| Cash Ratio | 0 | 0.02 |
| Operating Cash Flow Ratio | -0.25 | -0.08 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medicamen Organics Ltd | 6.30 | -6.83 | Neutral | -3.75 | -2.50 | -4.02 |
| 2 | Mono Pharmacare Ltd | 6.16 | 6.26 | Neutral | 8.00 | 1.75 | 3.00 |
| 3 | JFL Life Sciences Ltd | 6.07 | 9.54 | Neutral | 12.00 | 1.94 | 6.00 |
| 4 | Walpar Nutritions Ltd | 5.29 | 9.26 | Neutral | 6.66 | 2.09 | 3.00 |
| 5 | Mangalam Drugs and Organics Ltd | 4.50 | -1.07 | Neutral | -15.00 | -27.68 | -44.00 |
| 6 | Lasa Supergenerics Ltd | 4.39 | -2.61 | Highly Undervalued | -7.00 | -6.80 | -34.00 |
| 7 | Sunrest Lifescience Ltd | 4.17 | 7.06 | Highly Undervalued | 10.21 | 3.60 | 8.00 |
The management of Mono Pharmacare demonstrates potential alongside notable challenges. Revenue growth is robust, but profitability is strained by declining margins. Capital efficiency metrics such as ROCE and ROE are moderate. Increasing debt levels pose a concern, while stable shareholding patterns suggest continued promoter confidence. The focus should be on improving profitability and managing debt to enhance overall management effectiveness.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth | 37.60% | Strong revenue expansion. |
| Promoter Holding | 56.72% | Suggests confidence and alignment. | |
| CONS | OPM Decline | 5% | Indicates operational efficiency challenges. |
| Increasing Debt | ₹54 Cr. | Suggests rising leverage. |
Financial Performance & Growth
Mono Pharmacare exhibits strong revenue growth alongside challenges in maintaining profitability. Sales have grown, with a 37.60% increase in Mar 2025. However, the Operating Profit Margin (OPM) has decreased to 5% in Mar 2025. The increasing expenses indicate potential inefficiencies or rising costs that need to be addressed to translate revenue growth into stronger bottom-line results.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Sales Growth % | 353.28% | 37.60% | |
| OPM % | 6% | 5% | 5% |
Capital Efficiency & Returns
Mono Pharmacare's capital efficiency and returns are moderate. The Return on Capital Employed (ROCE) has slightly improved, increasing to 11% in Mar 2025. The Return on Equity (ROE) stands at 10%. These figures suggest that the company is generating reasonable returns on its capital and equity.
| Metric | Mar 2024 | Mar 2025 |
|---|---|---|
| ROCE % | 10% | 11% |
| ROE | 10% |
Financial Health & Prudence
Mono Pharmacare's financial health exhibits some challenges, particularly in debt management. Borrowings have increased to ₹54 Cr in Mar 2025. This increasing debt could pose risks if not managed carefully, as higher interest expenses can strain profitability.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Borrowings (₹Cr) | 40 | 41 | 54 |
| Interest (₹Cr) | 1 | 3 | 4 |
Strategic & Operational Indicators
Mono Pharmacare's operational efficiency, as indicated by its working capital management, presents concerns. The Cash Conversion Cycle (CCC) has decreased from 689 days in Mar 2023 to 179 days in Mar 2025. Similarly, the Working Capital Days have decreased from 703 days in Mar 2023 to 180 days in Mar 2025. These metrics suggest that Mono Pharmacare needs to improve its operational processes to free up cash and enhance overall financial performance.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Cash Conversion Cycle | 689 | 202 | 179 |
| Working Capital Days | 703 | 204 | 180 |
Mono Pharmacare faces moderate risk. Sales growth is strong, but profitability is a concern due to declining margins. Increasing debt levels elevate financial risk, and inefficient working capital management ties up cash. Stable promoter holding provides some reassurance. The company's ability to sustain growth and profitability while managing its financial obligations will determine its risk profile.
Off-balance sheet exposure quantification
There is no specific data available on off-balance sheet exposure quantification.
Contingent liability evaluation
There is no specific data available on contingent liability evaluation.
Foreign exchange or interest rate exposure
There is no specific data available on Foreign exchange or interest rate exposure.
Regulatory compliance cost trends
There is no specific data available on regulatory compliance cost trends.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1010.96Bearish
- SMA 2011.15Bearish
- SMA 5011.43Bearish
- EMA 1010.99Bearish
- EMA 2011.12Bearish
- EMA 5011.40Bearish
- DEMA 1010.87Bullish
- DEMA 2010.91Bullish
- DEMA 5011.02Bearish
- TEMA 1010.87Bullish
- TEMA 2010.87Bullish
- TEMA 5010.91Bullish
- MACD-0.16Bearish
- ADX15.21Weak Trend
- IndicatorValueSignal
- RSI39.96Neutral
- CCI-74.57Neutral
- ROC 90.46Bullish
- ROC 14-4.37Bearish
- ROC 25-4.78Bearish
- Stoch K7.84Oversold
- Stoch D3.92Oversold
- IndicatorValueSignal
- BB Upper11.63Neutral
- BB Middle11.15Neutral
- BB Lower10.68Neutral
- ATR0.13Low Volatility
- IndicatorValueSignal
- MFI27.46Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1011.11Bearish
- SMA 2011.28Bearish
- SMA 5011.60Bearish
- EMA 1011.07Bearish
- EMA 2011.22Bearish
- EMA 5011.55Bearish
- DEMA 1010.91Bullish
- DEMA 2010.96Bearish
- DEMA 5011.14Bearish
- TEMA 1010.88Bullish
- TEMA 2010.92Bullish
- TEMA 50N/AN/A
- MACD-0.20Bearish
- ADX12.62Weak Trend
- IndicatorValueSignal
- RSI41.23Neutral
- CCI-93.79Neutral
- ROC 9-4.37Bearish
- ROC 14-4.78Bearish
- ROC 25-7.20Bearish
- Stoch K7.02Oversold
- Stoch D6.60Oversold
- IndicatorValueSignal
- BB Upper11.86Neutral
- BB Middle11.28Neutral
- BB Lower10.70Neutral
- ATR0.21Low Volatility
- IndicatorValueSignal
- MFI42.80Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1011.21Bearish
- SMA 2011.44Bearish
- SMA 5012.13Bearish
- EMA 1011.18Bearish
- EMA 2011.41Bearish
- EMA 5011.73Bearish
- DEMA 1010.95Bearish
- DEMA 2011.03Bearish
- DEMA 50N/AN/A
- TEMA 1010.93Bullish
- TEMA 2010.92Bullish
- TEMA 50N/AN/A
- MACD-0.29Bearish
- ADX12.63Weak Trend
- IndicatorValueSignal
- RSI43.23Neutral
- CCI-111.86Oversold
- ROC 9-2.67Bearish
- ROC 14-7.20Bearish
- ROC 25-4.78Bearish
- Stoch K12.77Oversold
- Stoch D15.72Oversold
- IndicatorValueSignal
- BB Upper12.31Neutral
- BB Middle11.44Neutral
- BB Lower10.58Neutral
- ATR0.41Low Volatility
- IndicatorValueSignal
- MFI50.84Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1011.36Bearish
- SMA 2011.64Bearish
- SMA 5011.94Bearish
- SMA 10013.43Bearish
- SMA 20018.66Bearish
- EMA 1011.38Bearish
- EMA 2011.62Bearish
- EMA 5012.21Bearish
- EMA 10014.08Bearish
- EMA 20018.60Bearish
- DEMA 1011.10Bearish
- DEMA 2011.27Bearish
- DEMA 5010.87Bullish
- DEMA 1009.84Bullish
- DEMA 2009.39Bullish
- TEMA 1011.06Bearish
- TEMA 2011.10Bearish
- TEMA 5011.61Bearish
- TEMA 10010.37Bullish
- TEMA 200N/AN/A
- MACD-0.29Bearish
- ADX20.72Weak Trend
- IndicatorValueSignal
- RSI42.02Neutral
- CCI-99.58Neutral
- ROC 14-10.61Bearish
- ROC 25-15.12Bearish
- Stoch K15.10Oversold
- Stoch D18.51Oversold
- IndicatorValueSignal
- BB Upper12.54Neutral
- BB Middle11.64Neutral
- BB Lower10.74Neutral
- ATR0.56High Volatility
- IndicatorValueSignal
- MFI52.92Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 2012.00Bearish
- SMA 5017.30Bearish
- EMA 2012.92Bearish
- EMA 5017.02Bearish
- DEMA 2010.88Bullish
- DEMA 509.65Bullish
- TEMA 2011.69Bearish
- TEMA 50N/AN/A
- MACD-1.38Bullish
- ADX25.61Strong Trend
- IndicatorValueSignal
- RSI38.26Neutral
- CCI-75.73Neutral
- ROC 142.19Bullish
- ROC 25-29.39Bearish
- Stoch K32.26Neutral
- Stoch D35.67Neutral
- IndicatorValueSignal
- BB Upper13.71Neutral
- BB Middle12.01Neutral
- BB Lower10.30Neutral
- ATR1.22Low Volatility
- IndicatorValueSignal
- MFI53.48Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
- IndicatorValueSignal
- SMA 612.49Bearish
- SMA 1217.59Bearish
- SMA 2424.87Bearish
- EMA 613.81Bearish
- EMA 1217.40Bearish
- EMA 2425.37Bearish
- DEMA 611.19Bullish
- DEMA 1210.37Bullish
- DEMA 24N/AN/A
- TEMA 611.79Bullish
- TEMA 12N/AN/A
- TEMA 24N/AN/A
- MACDN/AN/A
- ADX12.11Weak Trend
- IndicatorValueSignal
- RSI42.10Neutral
- CCIN/AN/A
- ROC 25-72.02Bearish
- ROC 50N/AN/A
- Stoch KN/AN/A
- Stoch DN/AN/A
- IndicatorValueSignal
- BB Upper37.63Neutral
- BB Middle22.20Neutral
- BB Lower6.77Neutral
- ATR6.35Low Volatility
- IndicatorValueSignal
- MFI19.92Oversold